BR9808804A - Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas - Google Patents
Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicasInfo
- Publication number
- BR9808804A BR9808804A BR9808804-1A BR9808804A BR9808804A BR 9808804 A BR9808804 A BR 9808804A BR 9808804 A BR9808804 A BR 9808804A BR 9808804 A BR9808804 A BR 9808804A
- Authority
- BR
- Brazil
- Prior art keywords
- gastrointestinal tract
- treat
- upper gastrointestinal
- individual
- improve
- Prior art date
Links
- 210000002438 upper gastrointestinal tract Anatomy 0.000 title abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 230000004968 inflammatory condition Effects 0.000 title abstract 3
- 210000003238 esophagus Anatomy 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 210000002784 stomach Anatomy 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 208000025865 Ulcer Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 210000001035 gastrointestinal tract Anatomy 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 231100000397 ulcer Toxicity 0.000 title 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 5
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 5
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 5
- 239000000813 peptide hormone Substances 0.000 abstract 3
- 230000002496 gastric effect Effects 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 102400000321 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4675497P | 1997-05-16 | 1997-05-16 | |
| GBGB9715481.9A GB9715481D0 (en) | 1997-07-23 | 1997-07-23 | Methods of enhancing functioning of the upper gastrointestinal tract |
| US09/059,504 US6051557A (en) | 1997-05-16 | 1998-04-13 | Methods of enhancing functioning of the upper gastrointestinal tract |
| PCT/CA1998/000497 WO1998052600A1 (en) | 1997-05-16 | 1998-05-15 | Methods of enhancing functioning of the upper gastrointestinal tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9808804A true BR9808804A (pt) | 2001-09-18 |
Family
ID=27268946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9808804-1A BR9808804A (pt) | 1997-05-16 | 1998-05-15 | Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0981362B1 (https=) |
| JP (2) | JP4699576B2 (https=) |
| CN (1) | CN1264307B (https=) |
| AT (1) | ATE253375T1 (https=) |
| AU (1) | AU746633B2 (https=) |
| BR (1) | BR9808804A (https=) |
| CA (1) | CA2289652C (https=) |
| DE (1) | DE69819488T2 (https=) |
| DK (1) | DK0981362T3 (https=) |
| ES (1) | ES2210756T3 (https=) |
| MX (1) | MXPA99010523A (https=) |
| PT (1) | PT981362E (https=) |
| WO (1) | WO1998052600A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0981362T3 (da) * | 1997-05-16 | 2004-03-15 | Ontario Inc 1149336 | Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal |
| GB9905416D0 (en) * | 1999-03-09 | 1999-05-05 | Allelix Biopharma | Small molecules having GLP-2 like activity |
| RU2164349C1 (ru) * | 1999-07-27 | 2001-03-20 | Нижегородская государственная медицинская академия | Способ определения стоматологического статуса |
| WO2001041779A2 (en) * | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| ES2310192T3 (es) * | 2000-09-18 | 2009-01-01 | Sanos Bioscience A/S | Uso de peptidos glp-2. |
| WO2004035624A2 (en) | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| ES2427150T3 (es) | 2004-11-01 | 2013-10-29 | Nps Pharmaceuticals, Inc. | Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad |
| DE602006020123D1 (de) | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| AU2007319066B2 (en) | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| ES2555164T3 (es) * | 2010-08-30 | 2015-12-29 | Nps Pharmaceuticals, Inc. | Síntesis de fase sólida de h[Gly2]GLP-2 |
| AU2013255752B2 (en) | 2012-05-03 | 2017-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| EP3299023A4 (en) * | 2015-05-21 | 2019-03-20 | Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences | OXYGEN ARM-TREATED MESENCHYMM STEM CELL AND ITS USE |
| AU2017371516C1 (en) | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
| BR112019026711A2 (pt) | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2) |
| CN108273038B (zh) * | 2018-03-16 | 2019-03-19 | 中国人民解放军军事科学院军事医学研究院 | 防治肠型放射病的药物组合物 |
| CN110226566A (zh) * | 2019-07-12 | 2019-09-13 | 南京中医药大学 | 一种放射性口腔黏膜炎动物模型的造模方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK27885A (da) * | 1985-01-22 | 1986-07-23 | Novo Industri As | Fremstilling af peptider |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| DE60142885D1 (de) * | 1996-04-12 | 2010-10-07 | Ontario Inc 1149336 | Dem Glukagon ähnliches Peptid-2 |
| EP1012186B1 (en) * | 1996-12-06 | 2002-07-17 | Amgen Inc., | Use of a kgf protein product(s) and a glp-2 protein product(s) for the preparation of a medicament |
| US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| DK0981362T3 (da) * | 1997-05-16 | 2004-03-15 | Ontario Inc 1149336 | Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal |
-
1998
- 1998-05-15 DK DK98922546T patent/DK0981362T3/da active
- 1998-05-15 CA CA2289652A patent/CA2289652C/en not_active Expired - Fee Related
- 1998-05-15 PT PT98922546T patent/PT981362E/pt unknown
- 1998-05-15 WO PCT/CA1998/000497 patent/WO1998052600A1/en not_active Ceased
- 1998-05-15 AT AT98922546T patent/ATE253375T1/de active
- 1998-05-15 CN CN988073307A patent/CN1264307B/zh not_active Expired - Fee Related
- 1998-05-15 ES ES98922546T patent/ES2210756T3/es not_active Expired - Lifetime
- 1998-05-15 EP EP98922546A patent/EP0981362B1/en not_active Expired - Lifetime
- 1998-05-15 BR BR9808804-1A patent/BR9808804A/pt not_active Application Discontinuation
- 1998-05-15 AU AU75163/98A patent/AU746633B2/en not_active Ceased
- 1998-05-15 JP JP54974198A patent/JP4699576B2/ja not_active Expired - Fee Related
- 1998-05-15 MX MXPA99010523A patent/MXPA99010523A/es active IP Right Grant
- 1998-05-15 DE DE69819488T patent/DE69819488T2/de not_active Expired - Lifetime
-
2009
- 2009-07-22 JP JP2009171401A patent/JP2009280598A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK0981362T3 (da) | 2004-03-15 |
| EP0981362B1 (en) | 2003-11-05 |
| ES2210756T3 (es) | 2004-07-01 |
| PT981362E (pt) | 2004-03-31 |
| AU7516398A (en) | 1998-12-11 |
| WO1998052600A9 (en) | 2000-03-09 |
| DE69819488D1 (de) | 2003-12-11 |
| DE69819488T2 (de) | 2004-08-26 |
| WO1998052600A1 (en) | 1998-11-26 |
| CA2289652C (en) | 2012-02-28 |
| CN1264307A (zh) | 2000-08-23 |
| CN1264307B (zh) | 2013-10-30 |
| MXPA99010523A (es) | 2004-09-01 |
| JP4699576B2 (ja) | 2011-06-15 |
| HK1030160A1 (en) | 2001-04-27 |
| AU746633B2 (en) | 2002-05-02 |
| JP2009280598A (ja) | 2009-12-03 |
| EP0981362A1 (en) | 2000-03-01 |
| JP2002502369A (ja) | 2002-01-22 |
| CA2289652A1 (en) | 1998-11-26 |
| ATE253375T1 (de) | 2003-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9808804A (pt) | Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas | |
| Bienenstock et al. | The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions | |
| PT944396E (pt) | Composicoes e processos para melhorar o funcionamento gastrointestinal | |
| Di Mario et al. | Use of bovine lactoferrin for Helicobacter pylori eradication | |
| Keswani et al. | Role of salivary vascular endothelial growth factor (VEGF) in palatal mucosal wound healing | |
| Hulshof et al. | Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma | |
| Leis et al. | Facilitated neurogenic inflammation in unaffected limbs of patients with complex regional pain syndrome | |
| Wormsley | Response to duodenal acidification in man: III. Comparison with the effects of secretin and pancreozymin | |
| BRPI0408523A (pt) | métodos para melhorar um sintoma de esclerose múltipla em um indivìduo, para melhorar esclerose múltipla em um indivìduo mamìfero, para modular uma deficiência de il-10, ou um distúrbio associado com uma deficiência de il-10 em um indivìduo mamìfero, para tratar ou prevenir um distúrbio imunológico em um indivìduo mamìfero e para avaliar o tratamento de esclerose múltipla em um indivìduo mamìfero, composição farmacêutica, e, artigo de manufatura | |
| ATE451929T1 (de) | Von casein abgeleitete peptide und deren anwendung für die therapie | |
| US20050261194A1 (en) | Use of thymulin-like peptides for making pain-relieving medicines | |
| BR9607336A (pt) | Composições de aminoácidos e utilidades das mesmas em nutrição clinica | |
| Pan et al. | Cytokine transport across the injured blood-spinal cord barrier | |
| Nustede et al. | Plasma concentrations of neurotensin and CCK in patients with chronic pancreatitis with and without enzyme substitution | |
| BR0111506A (pt) | Complexos de droga macromoleculares e composições contendo os mesmos | |
| JP2013501736A (ja) | 神経変性の修復方法 | |
| ATE425763T1 (de) | Verwendung von zusammensetzungen mit der biologischen aktivitat der vasoaktiven intestinalen peptide zur behandlung von sarcoidose | |
| Joffe et al. | Increased muscle calcium A possible cause of mitochondrial dysfunction and cellular necrosis in denervated rat skeletal muscle | |
| Fukuda et al. | Adrenomedullin promotes epithelial restitution of rat and human gastric mucosa in vitro | |
| Herrera et al. | Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis resulting from gastroesophageal reflux. | |
| AU2003280523A1 (en) | Prevention, therapy and prognosis/monitoring in sepsis and septic shock | |
| Largiadèr | Proximal selective vagotomy without pyloroplasty: A randomized clinical study | |
| Mendizabal et al. | Effects of spermine on water absorption, polyethylene glycol 4000 permeability and collagenase activity in rat descending colon in vivo | |
| WO2022010942A3 (en) | Combination therapies for the treatment and prevention of biofilms | |
| Stoupel et al. | Beta‐Endorphins in acute myocardial infarction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: DE ACORDO COM O ART. 37, OPINO PELO INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE: NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96); AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI); NAO E CONSIDERADO INVENCAO, UMA VEZ QUE INCIDE NO ART. 10 (INCISO VIII) DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 38/27 (2006.01), A61K 38/26 (2006.0 |